The combination of bavencio and inlyta has achieved positive results in the phase 3 clinical trial of advanced renal cell carcinoma

RCC is the most common type of renal cancer, accounting for about 90% of all renal cancer The most common type of RCC is renal clear cell carcinoma, which accounts for about 70% of all RCC cases Between 20% and 30% of RCC patients had metastasis when they were diagnosed, and their first year survival rate was only 12% Its therapeutic prospect is not optimistic Today, Merck KGaA and Pfizer jointly announced that the combination therapy composed of bavencio (avelumab) and inlita (axitinib) significantly improved the progression free survival (PFS) of patients in the phase 3 clinical trial for advanced renal cell carcinoma (RCC) (http:// Previously, the combination therapy was recognized as a breakthrough therapy by FDA (http:// in December 2017 Bavencio bavencio is a humanized PD-L1 monoclonal antibody jointly developed by Merck and Pfizer in Germany By combining PD-L1, it can prevent cancer cells from using PD-L1 to evade the anti-tumor response of immune cells, and activate leukocytes (such as T cells) to participate in the killing of tumors In vitro experiments showed that the drug (http:// can induce NK cell-mediated direct tumor cell lysis through antibody dependent cell-mediated cytotoxicity (ADCC) Bavencio has been approved by FDA for the treatment of metastatic Merkel cell carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma (MUC) patients who have received chemotherapy About inlyta inlyta is a second-line RCC treatment drug developed by Pfizer and approved by many countries and regions Inlyta is a tyrosine kinase inhibitor (TKI) that binds to vascular endothelial growth factor receptor (VEGFR) and selectively inhibits VEGFR-1, - 2 and - 3 VEGFR is responsible for signal transduction and plays an important role in the origin and progression of various tumors Among them, VEGFR-1 plays an important role in tumor neovascularization VEGFR-2 plays an important role in endothelial cell proliferation, migration, survival and angiogenesis VEGFR-3 is involved in the formation of new lymphatics from existing lymphatics Inlyta can prevent the progression and metastasis of cancer by preventing new angiogenesis Javelin enal 101 is a global, multicenter, randomized (1:1) phase 3 clinical trial designed to evaluate the efficacy and safety of bavencio and inlyta combination therapy as a first-line therapy for advanced RCC compared to SUTENT monotherapy The trial was conducted in 866 patients to demonstrate whether bavencio and inlyta combination therapy is superior to SUTENT single drug therapy in prolonging PFS or total survival (OS) of PD-L1 + tumor patients In the interim analysis of the independent data monitoring committee (http:// the data showed that the combination therapy had a statistically significant improvement in PFS, whether in the group of patients with more than 1% PD-L1 expression or in the group of patients without considering the level of PD-L1 expression Javelin enal 101 will continue with the final analysis of the primary end point of overall survival (OS)